I believe the dosgae used for the phase 2B was the 2x2, moz can probably chime in on patient numbers as I cant re-call off the top of my head. There was prior art for 1.5 and this is what the FDA based their decision off. From their risk mitigation perspective, there is no point risking the 2x2 on a large scale (P3) if the 1.5 was just as effective.
I do agree with you, that it was a nice big waste of time and money.
Ann: Paradigm Receives $7.36m R&D Tax Incentive Refund, page-51
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.015(6.52%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 24.5¢ | 23.0¢ | $116.0K | 491.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 33682 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |